

Remarks/Arguments


The foregoing amendments to the specification are to insert the priority provisional application information, for which this application claims benefit. The Abstract has been added as a separate sheet, and should be inserted following the claims in the specification.

No amendments to the claims have been made, and no new matter has been added.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346


Thomas Digby
Attorney for Applicants
Reg. No. L0242

Date: October 14, 2005